Amgen vs NVIDIA: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amgen and NVIDIA side by side

1. 1980Amgen

   Applied Molecular Genetics is incorporated

   Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

2. 1983Amgen

   Nasdaq listing and the erythropoietin clone

   Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

3. 1984Amgen

   Kirin-Amgen joint venture formed

   Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

4. 1985Amgen

   G-CSF cloned, leading to Neupogen

   While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

5. 1989Amgen

   FDA approves Epogen

   The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

6. 1991Amgen

   Neupogen approved, giving Amgen a second franchise

   The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

7. 1991Amgen

   Amgen wins the erythropoietin patent fight

   On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

8. 1993NVIDIA

   Founding in Santa Clara

   Jensen Huang, Chris Malachowsky, and Curtis Priem founded NVIDIA on April 5, 1993, with a focus on 3D graphics for gaming and multimedia. The founding set the company on a parallel-processing path long before AI infrastructure became the main market.

9. 1999NVIDIA

   GPU Category Defined

   NVIDIA introduced the graphics processing unit concept in 1999. The milestone mattered because it framed graphics hardware as a specialized processor, a technical idea that later carried into accelerated computing and AI workloads.

10. 2001Amgen

    FDA approves Aranesp, the longer-acting EPO

    Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

11. 2002Amgen

    US$16 billion Immunex acquisition brings Enbrel in-house

    Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

12. 2006NVIDIA

    CUDA Opens GPUs to General Computing

    CUDA opened GPU parallel processing to scientists, researchers, and developers outside graphics. It became the software foundation that made NVIDIA hardware useful for machine learning, simulation, and other compute-heavy workloads.

13. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

14. 2012NVIDIA

    AlexNet Shows GPU Value for Deep Learning

    The AlexNet breakthrough used NVIDIA GPUs to win the ImageNet competition. The event helped convince researchers and engineers that GPUs could accelerate neural-network training at a scale CPUs could not match.

15. 2016NVIDIA

    DGX-1 AI Supercomputer

    Nvidia introduced the DGX-1 deep-learning supercomputer in 2016, its first system built specifically for artificial intelligence.

16. 2018NVIDIA

    RTX Brings Real-Time Ray Tracing to Graphics

    NVIDIA RTX brought real-time ray tracing into the company's graphics roadmap. The product line kept gaming and professional visualization tied to AI-enhanced rendering while Data Center was becoming more important.

17. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

18. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

19. 2020NVIDIA

    Mellanox Acquisition Adds Networking

    NVIDIA completed the Mellanox acquisition for about $7 billion. The deal mattered because large AI and high-performance-computing clusters depend on fast networking between accelerators, not only on individual GPU speed.

20. 2022NVIDIA

    Arm Acquisition Terminated

    NVIDIA and SoftBank terminated the proposed Arm acquisition because of significant regulatory challenges. The failed deal showed how closely governments watch control points in semiconductor architecture.

21. 2022NVIDIA

    Hopper H100 Announced

    Nvidia announced the Hopper-architecture H100 data-center GPU in March 2022.

22. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

23. 2023NVIDIA

    Grace CPU Enters Data Center Roadmap

    NVIDIA introduced its first data-center CPU, Grace, for large-scale AI and high-performance computing. The milestone expanded the platform from GPUs and networking into CPU-GPU system design.

24. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

25. 2024NVIDIA

    Blackwell Architecture Launched

    NVIDIA launched Blackwell as a data-center-scale architecture combining GPUs, CPUs, DPUs, interconnects, switch chips, systems, and networking adapters. The architecture became central to FY2026 Data Center demand.

26. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

27. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

28. 2026NVIDIA

    $215.9B FY2026 Revenue

    NVIDIA reported $215.9 billion of FY2026 revenue, $193.7 billion of Data Center revenue, and $120.1 billion of net income. The result showed how far AI infrastructure had moved the company beyond its original PC graphics market.

Acquisitions

Questions about Amgen vs NVIDIA